• Theraclion received FDA De Novo marketing authorization for Sonovein on November 4, 2026, opening the U.S. market for its non-invasive vein treatment.
• The pivotal study achieved a 96.8% great saphenous vein occlusion rate at 12 months, with no serious adverse events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theraclion SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261105040387) on November 05, 2026, and is solely responsible for the information contained therein.